Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TK-129 是具有口服活性的 KDM5B 的有效抑制剂,IC50值为44 nM,并且具有低毒性。TK-129 发挥心脏保护作用,通过抑制 KDM5B 和阻断 KDM5B 相关的 Wnt 通路。TK-129 可用于研究心血管疾病,它能在体内减少异丙肾上腺素诱导的心肌重塑和纤维化,并且在体外减少 Ang II 诱导的心脏成纤维细胞活化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | 待询 | 10-14周 | ||
50 mg | 待询 | 10-14周 | ||
100 mg | 待询 | 10-14周 |
产品描述 | TK-129 is an orally active, potent inhibitor of KDM5B with IC 50 of 44 nM that is low-toxicity. TK-129 shows cardioprotective effects by inhibiting KDM5B and blocking the KDM5B -associated Wnt pathway. TK-129 can be used in cardiovascular disease studies which reduce isoprenaline-induced myocardial remodelling and fibrosis in vivo as well as reduce ang II-induced activation of cardiac fibroblasts in vitro [1]. |
体外活性 | TK-129 mediates inhibition of KDM5B activity significantly reduces the activation, migration, and proliferation of myofibroblasts induced by Ang II in vitro [1]. TK-129 (10 μM; 48 h) shows low cytotoxicity in NRCFs and NRCMs [1]. TK-129 (0.1, 0.2, 0.3, 0.4, 0.5 μM; 48 h) can engage toand inhibit KDM5B activity in NRCFs [1]. Cell Cytotoxicity Assay [1] Cell Line: NRCFs and NRCMs Concentration: 10 μM Incubation Time: 48 h Result: Exhibited the cell survival rates were almost more than 90%. Western Blot Analysis [1] Cell Line: NRCFs Concentration: 0.1, 0.2, 0.3, 0.4, 0.5 μM Incubation Time: 48 h Result: Increased the expression level of KDM5B substrate H3K4me3 protein in a concentration-dependent manner. |
体内活性 | TK-129 (2 g/kg; p.o.; single) shows good bio-safety in mice [1]. TK-129 (50 mg/kg; p.o.; twice daily for 24 days) effectively reduces isoproterenol-induced pathological myocardial remodeling in vivo [1]. TK-129 (2 or 10 mg/kg; i.v. or p.o.; single) demonstrates favorable PK properties in vivo [1]. Animal Model: Wild C57BL/6 mice (8 to 10-week-old; half male and half female) [1]. Dosage: 2 g/kg Administration: Oral gavage, single. Result: Exhibited all mice in the acute toxicity group survived and gained weight normally, after 2 weeks. Animal Model: C57BL/6 mice (isoproterenol (ISO)-induced) [1]. Dosage: 50 mg/kg Administration: Oral gavage, twice daily for 24 days. Result: Alleviated myocardial remodeling induced by ISO in vivo. Animal Model: Male SD Rats (223.5-265.1 g) [1]. Dosage: 2 mg/kg (for i.v.); 10 mg/kg (for p.o.). Administration: Intravenous injection or oral gavage; single. Result: 1.19 Pharmacokinetic Parameters of TK-129 in Male SD Rats [1]. PO (10 mg/kg) IV (2 mg/kg) CL (L/h/kg) 9.9 4.2 V ss (L/kg) 33.4 2.7 T 1/2 (h) 2.4 0.4 T max (h) 0.4 - C max (ng/mL) 709.7 1229.1 AUC 0-24 (ng/mL h) 1038.2 479.6 F (%) 42.37 - |
分子量 | 305.38 |
分子式 | C15H23N5O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TK-129 Inhibitor inhibitor inhibit